同位素稀释-高效液相色谱-质谱联用技术检测大鼠血浆中的芥子气水解产物

应用同位素稀释-高效液相色谱-质谱联用技术(LC-MS/MS),建立了同时定量检测血浆中芥子气水解代谢产物硫二甘醇(TDG)和二羟乙基亚砜(TDGO)的方法.应用甲醇和乙腈混合溶剂沉淀染毒大鼠血浆中蛋白,采用ZORBAX-C18色谱柱(100 mm×3.0 mm,3.5μm),以5 mmol/L甲酸铵-甲醇梯度洗脱分离待测物.以d8-TDG为内标,在正离子多反应监测模式下定性和定量分析TDG和TDGO.方法学验证结果表明,TDG在5～800 μg/L和TDGO在0.5～80.0 μg/L范围内均呈良好的线性关系(r2＞0.991),定量限分别为5和0.5 μg/L,加标回收率在101％～118％之间,方法的日内和日间精密度(RSD)均小于10％.对SD大鼠(n=6)采用皮下注射方式进行染毒后采样测定,代谢动力学参数计算结果显示,TDG和TDGO的达峰时间(tmax)分别为30和60 min,峰值浓度(cmax)为(1724±227)μg/L和(301±115)μg/L,血浆浓度-时间曲线下面积(AUC)为(3286±249) μg· h/L和(1010±363) μg· h/L.     

固相萃取-高效液相色谱法测定人血浆中的川芎嗪

建立了高效液相色谱测定人血浆中川芎嗪浓度的方法。色谱条件:分析柱为Luna C18(150 mm×4.6 mm i.d.,5 μ m),流动相为甲醇-乙腈-醋酸盐缓冲液(pH 5.0)(体积比为50∶8∶42),流速1.0 mL/min,柱温40 ℃,检测波长280 nm。 血浆样品预处理采用C8固相小柱萃取法。方法的线性范围为25～5000 μg/L,线性相关系数为0.9999。高、中、低浓度 的川芎嗪在标准血浆样品中的平均提取回收率为96.72％～100.90％,日内和日间相对标准偏差(RSD)小于8.64％,准确度 为99.59%~103.26%,检测限为10 μg/L。该方法的各项效能指标符合生物样品的分析要求,可用于川芎嗪制剂的人体药 代动力学研究。     

液相色谱-质谱联用法测定人血浆中的阿莫西林

建立液相色谱–质谱联用法测定人血浆中的阿莫西林。在血浆样品中加入20μL 10μg/mL的阿莫西林-d4内标溶液,再经甲醇沉淀。色谱柱为Zorbax Eclipse XDB–C18(150 mm×2.1 mm,3.5μm),柱温为30℃,流动相为0.2%甲酸水溶液与0.2%甲酸甲醇溶液,采用梯度洗脱方式,流量为0.7 mL/min,进样体积为3μL;质谱采用电喷雾离子化方式和质谱多反应监测模式,检测离子为正离子。阿莫西林的质量浓度在0.05~10μg/mL范围内与其色谱峰面积呈良好的线性关系,相关系数为0.999 7,检出限为0.05μg/mL。测定结果的相对标准偏差小于3%(n=6),样品加标回收率为91.1%~97.3%。该方法操作简便,灵敏度高,专属性强,可用于测定人血浆中阿莫西林的含量。     

高效液相色谱/荧光法测定血浆、红细胞与尿液中的硫胺素及其磷酸酯

建立了同时测定血浆、红细胞、尿液中硫胺素(T)、一磷酸硫胺素(TMP)、二磷酸硫胺素(TDP)的柱前衍生/反相高效液相色谱-荧光检测法。样品经高氯酸除蛋白,铁氰化钾衍生后,采用反相色谱柱分离,荧光检测器测定,外标法定量。色谱柱为C18柱(250 mm×4.6 mm,5μm i.d.),流动相为0.2 mol/L KH2PO4溶液(pH 7.0,含0.000 3 mol/L四丁基氢氧化铵)-甲醇和甲醇-水,采用梯度程序进行洗脱,流速为0.8mL/min。荧光检测器激发波长为365 nm,发射波长为435 nm。结果表明:T,TMP在0.5~20.0μg/L,TDP在5.0~200.0μg/L质量浓度范围内呈良好的线性关系,相关系数分别为0.99,0.98,0.99。T,TMP,TDP的平均回收率为86.8%~110.2%,相对标准偏差(RSDs)为2.5%~10.9%。3种化合物在血浆及红细胞中的检出限(LODs)为0.03~0.35μg/L,定量下限(LOQs)为0.09~1.18μg/L。T在尿液中的检出限(LODs)为1.58μg/L,定量下限(LOQs)为5.26μg/L。该方法的准确度和精密度均较高,能够满足临床检测和科研需要。     

二维液相色谱法在线检测哈茨木霉发酵液中2460A含量

建立了在线检测哈茨木霉发酵液中微量2460A的二维液相色谱方法。利用Ultimate 3000双三元液相色谱仪,采用阀切换二维色谱技术,组合3根色谱柱实现2460A的在线净化、富集和含量检测。净化柱采用资生堂MF C8柱(10 mm×4.6 mm,5.0μm),富集柱采用资生堂MGC18柱(20 mm×4.6 mm,5.0μm),以水-甲醇为流动相,梯度洗脱,流速2.0 m L/min;二维分析柱采用Thermo Hypersil GOLD C18柱(250 mm×4.6 mm,5.0μm),以水-甲醇为流动相,梯度洗脱,流速1.0 m L/min;进样量1.0 m L;柱温40℃;检测波长424 nm。方法验证结果显示,2460A的线性范围为0.0025~10.0 mg/L(r=0.9981,n=8),检出限为1.2μg/L;定量限为2.5μg/L;方法回收率为88.0%~104.4%。     

超高效液相色谱-串联质谱法快速测定猪尿液中30种不同种类“瘦肉精”药物残留

建立了超高效液相色谱-串联质谱快速简单地同时测定猪尿液中30种不同种类“瘦肉精”药物(赛庚啶、可乐定及28种β-受体激动剂类)残留的方法.对液相色谱分离条件、MS/MS检测参数及样品前处理方式进行了优化.试样经5000 r/min离心5 min后直接经MCX柱净化,分别用3 mL水和3 mL甲醇淋洗,5％氨化甲醇进行洗脱,N2吹干后以流动相进行复溶,UPLC-MS/MS进行测定.结果表明,30种药物可在5.0 min内有效分离;各药物在0.1 ～ 10μg/L范围内呈良好的线性关系,相关系数均大于0.992;方法的检出限为0.1 μg/L,定量限为0.3 μg/L.在3个浓度水平下的平均回收率为67.6％ ～ 103.2％,日内、日间相对标准偏差分别为2.8％ ～ 16.8％和2.6％ ～15.8％.     

超高效液相色谱-串联质谱法测定人血浆中氯苯那敏

研究并建立了测定人血浆中氯苯那敏的超高效液相色谱-串联质谱(UPLCMS/MS)分析方法。血浆样品中加入内标,经2.5倍体积甲醇沉淀蛋白,涡旋离心后,取上清液进样测定。采用Waters ACQUITY UPLC HSS C18色谱柱(150×2.1mm,1.8μm)分离,以5mmol/L乙酸铵水溶液(含0.1%甲酸)-甲醇为流动相,梯度洗脱,流速为0.2 mL/min。氯苯那敏的线性范围为0.10~50.0μg/L,相关系数(r2)为0.9995,检出限和定量限分别为0.05、0.10μg/L。该方法操作简便、专属性强、灵敏度高,适用于人体血浆中氯苯那敏的测定。     

高效液相色谱法测定人血浆中奥氮平的浓度

 用高效液相色谱法测定了人血浆中奥氮平的浓度。色谱条件 :采用岛津LC 6A型高效液相色谱仪 ;色谱柱为ZorbaxODS (15 0mm× 4 6mmi d ,粒径 5 μm) ;流动相为V(5 0mmol/L磷酸钠缓冲液 ,pH 7 2 )∶V(甲醇 )∶V(乙腈 ) =12∶10∶3的溶液 ;检测波长为 2 70nm ;流速为 1 0mL/min ;柱温 40℃ ;灵敏度 0 0 0 5AUFS ;纸速 2mm/min。实验结果显示 ,在上述条件下 ,该方法的线性范围为 15 μg/L～ 12 0 0 μg/L(r =0 9988) ,最低检测限为 3μg/L ,血浆中奥氮平的平均回收率为 (97 0 2± 3 11) % ,测定结果的日内平均相对偏差为 3 86 % (n =15 ) 。     

反相高效液相色谱法测定人尿中利凡诺

建立了运用反相高效液相色谱法测定人尿中利凡诺的方法.采用Spherisorb C18色谱柱(250 mm×4.6 mm i.d.,5 μm);流动相: V(甲醇)∶V(乙腈)∶V(0.2 mol/L NH4Ac)=60∶37∶3;流速: 1.0 mL/min;柱温: 40 ℃;荧光检测器: 激发波长360 nm,发射波长500 nm.在5 ng/mL～1 μg/mL质量浓度范围内,呈现良好线性(r=0.9999),检出限为1 ng/mL.     

液相色谱-串联质谱法测定牛奶中伏马菌素FB1和FB2及其水解代谢物

建立了MAX混合阴离子固相萃取柱净化-高教液相色谱-串联质谱法测定牛奶中伏马菌素FB1和FB2及其水解代谢产物HFB1和HFB2的方法.牛奶样品经水稀释后,经MAX柱直接净化,甲醇洗脱得到FB1和FB2,经液相色谱-串联质谱负离子扫描测定,1％乙酸甲醇洗脱得到HFB1和HFB2,经液相色谱-串联质谱正离子扫描测定.结果表明,添加浓度为0.1～5.0 μg/L,牛奶中FB1和FB2及其水解代谢产物的回收率为76.4％～92.3％;相对标准偏差(RSD,n=5)为5.9％～12.5％;方法检出限(LOD)均为0.03 μg/L;定量限(LOQ)均为0.1 μg/L.本方法操作简单,灵敏度、回收率和重复性均良好.     

Development and validation of a highly sensitive LC-MS/MS method for quantitation of dexlansoprazole in human plasma: application to a human pharmacokinetic study

A highly sensitive, specific and simple LC-MS/MS method was developed for the simultaneous estimation of dexlansoprazole (DEX) with 50 μL of human plasma using omeprazole as an internal standard (IS). The API-4000 LC-MS/MS was operated under multiple reaction-monitoring mode using electrospray ionization. A simple liquid-liquid extraction process was used to extract DEX and IS from human plasma. The total run time was 2.00 min and the elution of DEX and IS occurred at 1.20 min. This was achieved with a mobile phase consisting of 0.2% ammonia-acetonitrile (20:80, v/v) at a flow rate of 0.50 mL/min on an X-terra RP 18 (50 × 4.6 mm, 5 μm) column. The developed method was validated in human plasma with a lower limit of quantitation of 2 ng/mL for DEX. A linear response function was established for the range of concentrations 2.00-2500.0 ng/mL (r > 0.998) for DEX. The intra- and inter-day precision values for DEX met the acceptance criteria as per FDA guidelines. DEX was stable in the battery of stability studies, viz. bench-top, auto-sampler and freeze-thaw cycles. The developed assay method was applied to an oral bioequivalence study in humans.     

HPLC-MS法同时测定5种抗癫痫药的血药浓度

癫痫是神经系统的一种常见病,不少患者需长期同时服用两种或两种以上抗癫痫药物.本研究采用高效液相色谱-电喷雾离子化质谱法同时测定5种常用抗癫痫药物卡马西平、氯硝西泮、阿普唑仑、艾司唑仑和苯妥英钠的血药浓度,色谱条件为以地西泮作为内标,Zorbax SB-C18(30mm×2.1mm,3.5μm)为色谱柱,甲醇-25mM的乙酸铵水溶液梯度洗脱,样品采用无水乙醚萃取.样品分析以离子阱质谱作为检测器,采用多重反应监测模式(MRM),选择MS2离子提高方法的专属性,5种抗癫痫药物在50～5000ng/mL浓度范围内均具有良好的线性关系,其日内、日间精密度均小于10%,方法回收率均大于90%.研究表明,本方法专属性强,灵敏度高,线性关系良好,适用于这5种抗癫痫药物的血药浓度监测、个体化给药方案的制定、药物滥用监测以及药代动力学研究.关键词高效液相色谱质谱抗癫痫药血药浓度药物分析     

液相色谱-串联质谱法测定水产品中麻醉剂MS-222残留

建立了液相色谱-串联质谱法测定水产品中麻醉剂3-氨基苯甲酸乙酯甲基磺酸盐(MS-222)残留量的方法。提取液为50%的甲醇及乙酸-乙酸钠缓冲溶液,提取液经C18固相萃取柱净化处理后用液相色谱-串联质谱仪进行测定,外标法定量。流动相为0.5%的甲酸溶液和乙腈(V:V=60:40),流速为0.2 mL/min。该方法的线性范围为0.001～1.0 mg/L,相关系数大于0.999,检出限为1μg/kg,定量限为2μg/kg。加标回收率可以达到80%～110%。     

Simultaneous determination of prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry

Oral prochlorperazine (PCZ), an antiemetic, undergoes extensive first-pass metabolism. The study developed a simultaneous analytical method for PCZ and its major metabolites, prochlorperazine sulfoxide (PCZSO), N-demethylprochlorperazine (NDPCZ) and 7-hydroxyprochlorperazine (PCZOH), in human plasma using an isocratic liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Deproteinized plasma specimens were separated using a 3 μm particle size octadecylsilyl column, and the run time was 10 min. The calibration curves were linear over the concentration ranges of 0.01-40 μg/L for PCZ, NDPCZ and PCZOH, and 0.05-80 μg/L for PCZSO. The intra- and inter-assay precisions and accuracies were within 7.0 and 99-104% and within 9.0 and 99-105%, respectively. The lower limits of quantification in human plasma were 10 ng/L for PCZ, NDPCZ and PCZOH, and 50 ng/L for PCZSO. The validated method was applied to the determination of plasma samples in 37 cancer patients receiving PCZ. Large interindividual variations were observed in plasma concentrations of PCZ, PCZSO, NDPCZ and PCZOH (relative standard deviation, 89.4, 88.7, 86.4 and 78.2%, respectively). In conclusion, this simultaneous LC-MS/MS method with acceptable analytical performance can be helpful for evaluating the pharmacokinetics of PCZ, including the determination of its metabolites in cancer patients and in clinical research.     

Simultaneous determination of five anti-epilepsy drugs in human plasma using liquid chromatography-mass spectrometry

A new liquid chromatography-mass spectrometry method for the determination of carbamazepine, clonazepam, alprazolam, estazolam and phenytoin in human plasma has been developed by using diazepam as an internal standard. Chromatographic separation was performed on a Zorbax SB-C18 column (30 mm × 2.1 mm, 3.5 μm) with a mobile phase consisting of methanol and aqueous 25 mM ammonium acetate using gradient elution. A diethyl ether extraction method was used for the extraction of five anti-epilepsy drugs. The final extract was injected for analysis by LC-MS/MS. The method was validated within the concentration range of 50–5000 ng mL^?1 for five anti-epilepsy drugs. The precision of the assay (RSD%) was less than 10% at all concentration levels within the tested range. The method recoveries for all samples were more than 90%. The results indicate that the method is specific, sensitive and accurate, and suitable to study the pharmacokinetics, to adjust the dosage for individual administration, and to monitor the drug-concentration and drug abuse of the five anti-epilepsy drugs.     

固相萃取-液相串联质谱测定人血浆中安妥沙星的药物浓度

建立了专属性更高的固相萃取(SPE)-高效液相三重四级杆质谱(LC-MS/MS)测定人血浆中安妥沙星的方法。血浆样品经弱阴离子固相萃取柱净化后,洗脱吹干,复溶后进行检测。采用Agilent Eclipse plusC8色谱柱,流动相为10mmol/L乙酸铵(pH 3.5)-甲醇(35∶65,V/V),流速为0.35mL/min,选择离子检测,线性范围为7.0～5080μg/L,R>0.996,检出限0.5μg/L,绝对回收率>77.6%,日间相对标准偏差<7.9%。将本方法用于受试者给药后的血药浓度测定,结果满意。     

A rapid LC-MS/MS method for quantitation of eszopiclone in human plasma: application to a human pharmacokinetic study

A highly reproducible, specific and cost-effective LC-MS/MS method was developed for simultaneous estimation of eszopiclone (ESZ) with 50 μL of human plasma using paroxetine as an internal standard (IS). The API-4000 LC-MS/MS was operated under the multiple reaction-monitoring mode using the electrospray ionization technique. A simple liquid-liquid extraction process was used to extract ESZ and IS from human plasma. The total run time was 1.5 min and the elution of ESZ and IS occurred at 0.90 min; this was achieved with a mobile phase consisting of 0.1% formic acid-methanol (15:85, v/v) at a flow rate of 0.50 mL/min on a Discover C(18) (50 × 4.6 mm, 5 μm) column. The developed method was validated in human plasma with a lower limit of quantitation of 0.1 ng/mL for ESZ. A linear response function was established for the range of concentrations 0.10-120 ng/mL (r > 0.998) for ESZ. The intra- and inter-day precision values for ESZ were acceptable as per FDA guidelines. Eszopiclone was stable in the battery of stability studies, viz. bench-top, autosampler and freeze-thaw cycles. The developed assay method was applied to an oral bioequivalence study in humans.     

分散固相萃取结合液相色谱-串联质谱法测定饲料中8种脂溶性着色剂

建立了饲料中8种脂溶性着色剂(对位红、苏丹红Ⅰ、苏丹红Ⅱ、苏丹红Ⅲ、苏丹红Ⅳ、苏丹红7B、苏丹红G、苏丹黄)含量的液相色谱-串联质谱测定方法。饲料样品中脂溶性着色剂经乙腈提取,离心后上清液采用分散固相萃取净化,净化液稀释后进行LC-MS/MS分析。样品测定时采用Acquity BEH C18色谱柱进行色谱分离,以0.2%甲酸溶液-乙腈作为流动相进行梯度洗脱,电喷雾正离子(ESI+)模式电离,多反应监测(MRM)模式检测,同位素稀释内标法定量。8种脂溶性着色剂在1.0~200μg/L范围内线性关系良好,相关系数(r~2)均大于0.998;在饲料中的方法检出限为5.0μg/kg,定量下限为10μg/kg。在10,50,500μg/kg加标浓度下8种脂溶性着色剂的回收率为102%~111%,批内相对标准偏差(RSD)为2.8%~8.0%,批间RSD为2.8%~7.8%。该方法能满足饲料样品中脂溶性着色剂监控的需要。     

液相色谱-串联质谱法测定小型家用电器塑料部件中双酚A

建立了小型家用电器塑料部件中双酚A的液相色谱-串联质谱(LC-MS/MS)检测方法。采用快速溶剂萃取仪对样品进行萃取,以Sep-Pak C18固相萃取柱净化,甲醇-水(含有0.05%氨水)混合液作为流动相,负离子模式下进行MS/MS检测。结果表明: 该方法在5～100 μg/L范围内线性关系良好,相关系数(r2)为0.9991。在10、25和75 μg/kg 3个添加水平下,双酚A的平均回收率为95.2%～109.7%,相对标准偏差均小于3.8%,检出限为10 μg/kg。该方法操作简便,灵敏度高,适用于家用电器塑料部件中双酚A的残留分析。     

液相色谱-串联质谱法快速筛查马饲料中39种违禁药物

建立了同时快速筛查和确证马饲料中39种赛马违禁药物(包含抗心率失常类药物、抗惊厥类药物、止痉挛类药物、抗疟疾类药物、刺激剂、麻醉剂及大麻酚类药物)的液相色谱串联质谱(HPLC-MS/MS)分析方法。样品粉碎后分别经1 mmol/L HClO4溶液和酸化乙腈溶液提取,并通过混合型固相萃取柱净化。采用Agilent Zorbax SB(10.0 cm×2.1 mm i.d.,3.5 μm) 色谱柱,以0.4%甲酸水溶液和0.4%甲酸乙腈为流动相进行梯度洗脱,正离子多反应监测(MRM) 模式下检测。方法对空白饲料3个加标水平下的平均回收率为58%~116%,相对标准偏差为1.6%~20.4%,各类药物线性良好(r2＞0.99)。方法检出限(S/N≥3)和定量下限(S/N≥10)分别为0.2~25.0 μg/kg和1.0~40.0 μg/kg,其中超过67%药物的检出限在2.5 μg/kg以下。实验结果表明,该方法分析时间短,灵敏度、精密度良好,适用于马饲料中上述几类药物的快速筛查和测定。